Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca looks to combos after effective ex-Ardea drug shows serious adverse effects

This article was originally published in Scrip

Executive Summary

AstraZeneca's top-line gout data released 13 December shows efficacy for lesinurad but also a worrying range of serious adverse events. While the Phase III LIGHT study was designed to test lesinurad's utility in patients who cannot tolerate some standard-of-care and commonly used gout drugs, lesinurad's adverse event profile might threaten its regulatory or market success. Now the company will look to the drug's performance in combinations with standard gout treatments.


Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts